% | $
Quotes you view appear here for quick access.

Virgin Media, Inc. Message Board

Posts containing “”: 2386261 results
SortMost Relevant  |  Newest  |  Oldest Expand all messages
  • Reply to

    Shooting Star candlestick patter

    by artbyxxx Mar 24, 2015 10:37 AM

    What you write is complete b.s. Man are you full of hot air! You are exactly as I said you are: a one trick pony. Okay you are not a believer in FB stock. We know that already from your 1000 posts. Yet you continue to pound the table like the nutjob who wears the sign, "The world is ending Dec 31. 2015." You say you're trying to help people. Bull----. You say tomato, I say to-ma-to. You gloss over the elements like monetization from 35 + businesses and choose to harp on the obvious: PE. Everyone in the market knows about PE. You're such a genius. These 35+ businesses are already bringing in revenue despite the so-called competition. FB has told the market we don't care when you want us to talk about monetization. We will talk about when WE decide it's best. You can keep on bashing this stock. You can keep on using whatever numbers and technicals and overall info you feel will back up your argument. In the end it won't work. Wall Street wants FB's share price to ascend. One example of how full of s--- you are: user engagement. Anybody with a brain in his head knows that FB is approaching user saturation, although I believe with the launching of drones they will start to add on users from the other two thirds of the world NOT on the internet. Why don't you write about ARPU (Average Revenue Per User)? FB stands poised to grow that number exponentially. You know this metric. Of course, you'll write some other horses---- that is so far from the truth just to back up your argument. Who are you working for anyway? Nobody posts day in and day out unless they're on somebody's payroll. And if you're NOT being paid, then you really are a sad story. See you higher. Much higher.

  • South Korea chose a state-run aircraft maker on Monday as the sole preferred bidder for a contract to develop a midlevel fighter jet with the help of Lockheed Martin Corp.

  • Reply to

    company seeks acquisitions

    by natsfan973 Mar 25, 2015 10:15 PM


  • msft productivity software used to create the interop data....

    Sentiment: Strong Buy

  • Reply to

    Start buying here

    by giraffe_road_kill Mar 20, 2015 3:45 PM


  • british airways, british airways flights, british airways accounts, frequent flyers accounts of british The British airlines has frozen the accounts of frequent flyers which have been hacked, while it resolves the issue.

  • Reply to


    by andrew22690 Mar 28, 2015 10:28 PM

    Peter you spilled some fecas in your eye, you obviously cannot read between the lines

  • The Consumer Financial Protection Bureau (CFPB) has announced more rules (proposed) this week in order to control payday loan companies.

  • How can i access yahoo finance premium service?

  • stock price of just $ trading at .19??
    In reading the questions/answers here on the board this stock should be commanding a much higher price tag…am I missing something ??


  • Reply to

    Unemon 1

    by jahn2015 Mar 29, 2015 9:01 PM

    Hover your mouse over his name and an icon pops up to the right saying flag. Click the down arrow and select. Ignore.

  • Reply to

    Why has ya-hoe shutdown this board?

    by shaftard Mar 29, 2015 1:34 PM

    The boards is infested by permabears, who are bigots, atheists, and communists. In addition, most of them are just plain broke. Yahoo has no reason to promote this board.

  • InfoWorld - Oct 12, 1998 - Page 40
    The Aventail ExtraNet Center is slated for release on Nov. 14 for Windows NT, Linux, BSD/OS, Digital Unix, Sun Solaris, AIX, and HP-UX servers and Windows

  • Program#/Poster#: 486.02
    Presentation Title: Delayed treatment with Anatabine after repetitive mild TBI normalizes spatial memory impairment
    Location: WCC 156
    Presentation time: Tuesday, Nov 18, 2014, 8:15 AM - 8:30 AM
    Topic: ++C.10.d. Brain: Therapeutic strategies
    Authors: *S. FERGUSON1,2, B. MOUZON1,2, L. ABDULLAH1,2, G. CRYNEN1, V. MATHURA1, M. MULLAN1,2, F. CRAWFORD1,2;
    1Roskamp Inst., Sarasota, FL; 2James A Haley Veteran's Hosp., Tampa, FL
    Abstract: Traumatic brain injury (TBI) is a serious illness which on average strikes one person every 15 seconds in the US. TBI carries long term consequences, even after mild TBI, which are the most common and comprise as many as 75% of all TBI cases. Despite the mild nature of the initial insult, secondary injury neuroinflammatory and neurodegenerative processes are initiated and continue for weeks and months afterward. Previously we reported on the potential of anatabine to affect neuroinflammation and improve memory at a long term timepoint when taken acutely after mild TBI. We have characterized anatabine’s effects in a crossover study as a continuation of our previous work. We treated mice orally with anatabine in a closed head injury model of mild TBI. Anatabine was administered in their water starting 30 minutes after injury and continuing for 9 months. Untreated mice received regular water, and anesthesia controls were used for both the treated and untreated groups (r-sham). At a chronic timepoint 6 months after injury we saw a significant improvement of spatial memory of the anatabine treated r-mTBI mice compared to untreated r-mTBI mice, with anatabine treated r-mTBI mice performing as well as r-sham mice. At 9 months, 4 mice per group were euthanized for neuropathological analyses, revealing regionally-specific reductions in IBA1 and GFAP staining in the anatabine treated r-mTBI mice. We have continued to characterize the surviving mice using a crossover study design. Both r-mTBI and r-sham mice that were previously untreated were given anatabine starting at the 9 month timepoint. Mice that previously received anatabine began receiving regular water only. The mice were re-evaluated using the Barnes maze at 12 and 18 months post-injury. Although r-mTBI mice that began taking anatabine at 9 months post-TBI continued to perform worse than shams at the 12 month timepoint, by 18 months injured mice that had previously performed significantly worse than sham mice were now performing as well as shams. Pathological analysis of the brain tissue once again reveals regionally-specific differences that appear to be driven by anatabine treatment. Anatabine shows strong potential at improving memory following TBI, and may have a long therapeutic window, even to chronic timepoints; these data support further preclinical exploration of anatabine as a treatment for TBI. Dr. Michael Mullan is the CEO of Rock Creek Pharmaceuticals which sells anatabine as a nutraceutical supplement. The anatabine used in this study was provided by Rock Creek Pharmaceuticals. None of the other authors receive remuneration from Rock Creek Pharmaceuticals. This study was funded by the Roskamp foundation.
    Disclosures: S. Ferguson: None. B. Mouzon: None. L. Abdullah: None. G. Crynen: None. V. Mathura: None. M. Mullan: A. Employment/Salary (full or part-time):; Rock Creek Pharmaceuticals. F. Crawford: None.
    Support: Roskamp Foundation
    DoD Grant W81XWH-13-1-0253


    But only the Gruberites brought it to 46MM under the guise of "stimulating" the economy....

  • Reply to

    While the Mideast is in free fall

    by springer_1994 Mar 27, 2015 7:40 AM

    Yawn - you're amusement comes from looking at the mirror and seeing the reflection of the classic liberal clown you see every day. You're IQ and "retorts" prove it.

  • Reply to

    Still can't come up...

    by theman3311 Mar 29, 2015 5:21 PM

    There are no Reasons to sell at this point, even true for the shorts!

  • Reply to

    markets are now closed.. now we wait

    by investguy571 Mar 27, 2015 4:04 PM

    Well.. The wait is over!

  • Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile
    -- Study Advances Development of Preventive Approach for C. difficile Infection --
    ROCKVILLE, Md., March 30, 2015 /PRNewswire/ - Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome, today announced the initiation of a Phase 2a clinical trial to evaluate the gastrointestinal (GI) antibiotic-degrading effects and the safety of SYN-004, the Company's investigational oral beta-lactamase enzyme designed to protect the microbiome and prevent C. difficile infection (CDI). C. difficile is the leading type of hospital acquired infection and is frequently associated with intravenous (IV) antibiotic treatment. Beta-lactam antibiotics are a mainstay in hospital infection management, and include commonly used penicillin and cephalosporin antibiotics, such as ceftriaxone.
    "We are excited to start our Phase 2a trial of SYN-004 on schedule. Synthetic Biologics believes SYN-004 holds the potential to protect the microbiome from the damaging effects of antibiotics and dramatically reduce C. difficile infections through prevention vs. treatment," said Jeffrey Riley, Chief Executive Officer of Synthetic Biologics. "We anticipate reporting topline results from this Phase 2a clinical trial during the second quarter of 2015, and initiating the Phase 2b clinical trial in the second half of this year."
    The U.S. Centers for Disease Control and Prevention (CDC) has categorized C. difficile as an "urgent public health threat," and has stated the need for research to better understand the role of normal gut bacteria. SYN-004 is intended to block the unintended harmful effects of antibiotics within the GI tract and maintain the natural balance of the gut microbiome, potentially preventing the 1.1 million C. difficile infectionsi and 30,000 C. difficile-related deathsii in the United States each year. During 2012, approximately 14 million U.S. patients received approximately 118 million doses of IV beta-lactam antibioticsiii that could be inactivated in the GI tract by SYN-004.
    The Phase 2a randomized, multi-center, open-label study is expected to evaluate the ability of two different dose strengths of SYN-004 to degrade residual IV ceftriaxone in the GI tract of up to 20 healthy participants with functioning ileostomies, without affecting the concentrations of IV ceftriaxone in the bloodstream. The study consists of two treatment phases for all participants: 1) the administration of IV ceftriaxone alone, and 2) the administration of one of two doses of oral SYN-004 and IV ceftriaxone. Chyme samples will be collected from the participants to measure the ability of SYN-004 to degrade the residual antibiotic. Participants will be enrolled at up to four trial sites located in the United States and Canada.
    About Synthetic Biologics, Inc.
    Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage biotechnology company developing pathogen-specific therapies for serious infections and diseases, with a focus on protecting the microbiome. The Company is developing an oral biologic to protect the gut microbiome from intravenous (IV) antibiotics for the prevention of C. difficile infection, an oral statin treatment to reduce the impact of methane producing organisms on irritable bowel syndrome with constipation (IBS-C), and in collaboration with Intrexon Corporation (NYSE: XON), a monoclonal antibody combination for the treatment of Pertussis. In addition, the Company is developing a Phase 2 oral estriol drug for the treatment of relapsing-remitting multiple sclerosis (MS) and cognitive dysfunction in MS.

    Sentiment: Strong Buy